SB 239063, , >98% (HPLC)

SB 239063, , >98% (HPLC)

Stock Code: 3573886
Manufacturer Part No: S0569-25MG
Order Now for 7 day delivery
Click Add to Quote for price and delivery
Quantity: - +

Application


SB 239063 has been used to determine the roles of c-Jun N-terminal kinase (JNK), p38 MAP kinase, and extracellular signal regulated protein kinase (ERK)/p42/p44 mitogen activated protein kinase (MAPK) on the viability and apoptosis of cardiomyocytes under glutathione S-transferase (GST) inhibition. It has also been used in neuron-microglia conditioned media (CM) experiments and pharmacokinetics.


Biochem/physiol Actions


Potent p38 MAP kinase inhibitor. Selective for α and β. No activity against γ and δ isoforms.


Features and Benefits


This compound was developed by GlaxoSmithKline. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.


General description


SB 239063 helps to decrease neutrophilia, inflammatory cytokines, matrix metallopeptidase 9 (MMP-9) and fibrosis in the lung.


Legal Information


Sold for research purposes under agreement from GlaxoSmithKline


Packaging


5, 25 mg in glass bottle

Colourwhite
Quality Level100
mp206-207.2 °C
InChI keyZQUSFAUAYSEREK-WKILWMFISA-N
InChI1S/C20H21FN4O2/c1-27-20-22-11-10-17(24-20)19-18(13-2-4-14(21)5-3-13)23-12-25(19)15-6-8-16(26)9-7-15/h2-5,10-12,15-16,26H,6-9H2,1H3/t15-,16-
ManufacturerSIGMA-ALDRICH
Formpowder
Assay>98% (HPLC)

There are no downloads for this product.